‘Gonzalez Diet’ to Be Tested in Pancreatic Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 9
Volume 8
Issue 9

NEW YORK-An innovative clinical trial to be conducted at Columbia University is now recruiting patients with advanced pancreatic cancer. The patients will test the effectiveness of the “Gonzalez regimen,” which combines a strict diet of fresh fruits, vegetable juices, dietary supplements, and pancreatic enzyme extracts with a “detoxification” program. John Chabot, MD, a surgical oncologist at Columbia, is the principal investigator.

NEW YORK—An innovative clinical trial to be conducted at Columbia University is now recruiting patients with advanced pancreatic cancer. The patients will test the effectiveness of the “Gonzalez regimen,” which combines a strict diet of fresh fruits, vegetable juices, dietary supplements, and pancreatic enzyme extracts with a “detoxification” program. John Chabot, MD, a surgical oncologist at Columbia, is the principal investigator.

The researchers are seeking 72 to 90 patients with advanced pancreatic cancer for the phase III randomized study, which is being sponsored by the NCI’s newly established Office of Cancer Complementary and Alternative Medicine. Half the patients will receive standard therapy with gemcitabine (Gemzar), while the other half will take the Gonzalez regimen.

Pilot Study Promising

The trial, which was given a 5-year, $250,000 grant, is applying scientific methods to assess the efficacy of this alternative treatment. The NCI agreed to test the regimen after Nicholas Gonzalez, MD, a New York endocrinologist, conducted a pilot study of his protocol from 1993 to 1996. The results, reported earlier this year in Nutrition and Cancer, showed that 9 of 11 pancreatic patients survived for 1 year, five survived for 2 years, and four survived for 3 years.

For information about patient entry to the trial, contact Michelle Gabay, RN (212-305-9468) at Columbia Presbyterian Cancer Center.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Related Content